Source - WSJ
China’s Food and Drug Administration expedites domestic drug applications to encourage innovation. But its lengthy drug-approval process for foreign companies means none of the direct-acting antiviral agents that have been shown to cure more than 90% of hepatitis C patients within a few months have been approved in China, which has among the highest rates of the disease in the world with an estimated 10 million people infected.
Chinese patients tired of old-generation therapies such as interferon injections have increasingly traveled overseas to access the new therapies.
Continue reading....
No comments:
Post a Comment